Skip to content

Released Nov 14, 2022, after the close

10-Q filed Nov 14, 2022, 45 days after period end · 0001628280-22-029889

Q3 2022 · 10-Q
Revenue—
Net Income-$29.35MN/M vs Q3 2021N/M vs Q2 2022
EPS Diluted-$1.61N/M vs Q3 2021N/M vs Q2 2022
Operating Income-$31,655,000N/M
Operating Cash Flowderived-$30,098,000—
Free Cash Flowderived-$34,889,000—

What the release said

No earnings release is on file for this quarter. Its figures came with the 10-Q.

Same quarter

MetricQ3 2022Q3 2021
Net Income-$29.35M-$16.41M
EPS Diluted-$1.61-$1.52

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Prime Medicine, Inc. · CIK 1894562 · Engraved from SEC EDGAR